News & Events

06/05/2020

Fidia's measures and initiatives in response to the COVID-19 emergency

The company has undertaken extensive safety measures for its employees straight after the outbreak, while ensuring continuity of operations and production

Abano Terme (PD), May 5th 2020 – Fidia, Italian multinational company, with R&D, manufacturing, marketing and sales capabilities, and an extensive product portfolio mainly based on hyaluronic acid, is deeply committed to providing all the necessary support in response to the current situation with…
27/04/2020

COVID-19: communication to Partners, Customers and Suppliers

Health and safety, a top priority for Fidia

According to Fidia Farmaceutici S.p.A mission and policy, health and safety of people, and of course of our employees, are absolute priority.This is why we decided to reduce potential risks, asking our colleagues, partners, visitors, ecc… to work remotely as much as possible, as well as to strictly…
17/07/2019

Fidia presents New Data on HYMOVIS® effects on Cartilage Volume and Type II Collagen Turnover at Osteoarthritis Research Society International (OARSI) World Congress

Announcement title: "Hyaluronan Derivative Hymovis® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee: Data from MOKHA (MRI, BiOmarkers, Knee, Hymovis®, OsteoArthritis) Study"

Press release will be translated into Russian and published
25/09/2017

FIDIA PHARMA GROUP LAUNCHES BRAND NEW HYMOVIS WEBSITE

Let's move, with Hymovis!

We are pleased to announce the release of Fidia Pharma Group's new www.hymovis.net website, designed with a user-friendly navigation, and updated with the latest information on the product. Our objective is to provide our international visitors with an easier way to learn about Hymovis and to…
19/07/2017

FIDIA FARMACEUTICI S.P.A. LEADS EUROPEAN ORTHOPEDIC BIOMATERIALS MARKET

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021

“Fidia Farmaceutici has invested in research and development of hyaluronic acid-based products for more than 70 years. Today, Fidia is growing its product portfolio with new, innovative solutions to meet challenges in the field of osteoarthritis using science, our legacy and our drive.”

PARSIPPANY, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is…
17/03/2017

SLEEP DISORDERS MAY AFFECT HEALTH, PERFORMANCE AT WORK AND QUALITY OF LIFE

An estimated 9 million people in Italy suffer from sleep disorders, that partially contribute to poorer work performance, general health and quality of life.

Management of sleep disorders may result in significant improvement of general health. The first step is talk to the primary care provider.

Social media use is rapidly increasing, as well as daytime and bedtime use of computers, including devices such as smartphones, tablets and laptops. Work, stress, menopause, advancing age or a variety of underlying medical conditions affecting the general population, may be responsible for those…
28/02/2017

FIDIA PHARMA GROUP EXPECTED TO BE A KEY PLAYER IN THE OPHTHALMIC SECTOR

The Company is finalizing the acquisition of Italian Sooft/Oox Group

The Group is positioned among the top four companies in this market segment, and is engaged in the development of products for all major eye diseases.

As announced at the end of 2016, Fidia has finalized the first step to the successful acquisition of the majority stake in the Sooft/Oox Group, through a legally binding agreement that will be executed over the next few weeks. Sooft/Oox is an Italian group active in the ophthalmic sector, with a…
11/11/2016

HYMOVIS® RECEIVES PERMANENT, PRODUCT-SPECIFIC J-CODE FROM THE CENTER FOR MEDICARE AND MEDICAID SERVICES (CMS)

HYMOVIS® offers a convenient two-dose regimen

HYMOVIS® is a true innovation in HA viscosupplementation. Its unique molecular structure results in enhanced biomechanical properties and long-lasting efficacy, all in a convenient two-dose regimen

Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services (“CMS”) has assigned its product HYMOVIS® a unique Healthcare Common…

Fidia
Farmaceutici S.p.A.
Website

Find out our Corporate Website:

Go to the website

Other product websites

Direct link to:

Key Business Areas

Drawing on the strengths of the parent company, Fidia Pharma Russia product portfolio focalizes primarily on joint healthcare.

Fidia Pharma Russia is focused on providing consumers with innovative products that offer quality, safety and performance.